Firefly Bio Acquired by Johnson & Johnson | Healthcare M&A Deal

Johnson & Johnson has acquired Firefly Bio, a healthcare services other business in the United States, for $1 billion. Firefly Bio focuses on oncology-related research and development, supporting expansion of clinical and translational capabilities within healthcare M&A. Johnson & Johnson acquisitions in healthcare services other acquisition categories aim to strengthen its oncology pipeline through a platform acquisition of specialized expertise. The announced strategic acquisition is structured as a platform acquisition by a strategic buyer, with deal size over $100M and terms valued at $1 billion.